| [1] |
Deng L, Guo SJ, Liu YP, et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. BMC Public Health, 2025, 25(1): 636. doi:10.1186/s12889-025-21851-z
|
| [2] |
Eckardt KU, Delgado C, Heerspink HJL, et al. Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2023, 104(5): 888-903.
|
| [3] |
GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10518): 2461-82.
|
| [4] |
Wang LH, He YN, Han C, et al. Global burden of chronic kidney disease and risk factors, 1990-2021: an update from the global burden of disease study 2021[J]. Front Public Health, 2025, 13: 1542329. doi:10.3389/fpubh.2025.1672557
|
| [5] |
Yan MT, Chao CT, Lin SH. Chronic kidney disease: strategies to retard progression[J]. Int J Mol Sci, 2021, 22(18): 10084. doi:10.3390/ijms221810084
|
| [6] |
杨一歌, 李 鹤, 张秀立, 等. 慢性肾病及相关并发症治疗药物研究进展[J]. 药学学报, 2022, 57(9): 2682-95.
|
| [7] |
Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus[J]. Nat Rev Nephrol, 2024, 20(7): 473-85. doi:10.1038/s41581-024-00820-6
|
| [8] |
罗卫红, 李佳欣, 蒋建平, 等. 急性肾损伤进展至慢性肾脏病的临床特征和危险因素: 前瞻性、观察性队列研究[J]. 中华肾脏病杂志, 2020, 36(8): 625-30. doi:10.3760/cma.j.cn441217-20200528-00112
|
| [9] |
Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference[J]. Kidney Int, 2021, 100(3): 516-26. doi:10.1016/j.kint.2021.06.028
|
| [10] |
Baker LW, Ovincy C, Souvalian L, et al. Contemporary management of advanced chronic kidney disease: an evidence-based review[J]. Eur J Intern Med, 2026, 143: 106557. doi:10.1016/j.ejim.2025.106557
|
| [11] |
Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease[J]. Nephrol Dial Transplant, 2025, 40(): i3-17. doi:10.1093/ndt/gfae212
|
| [12] |
董玉君, 包骏轶, 徐书杭. 基于《黄帝内经》“咸入肾”探讨中医防治慢性肾脏病[J]. 亚太传统医药, 2024, 20(2): 199-202.
|
| [13] |
王 筝, 刘文康, 冯桃花, 等. 慢性肾脏病毒瘀相关病机探讨[J]. 河北中医, 2019, 41(12): 1893-5, 1920.
|
| [14] |
Qian TY, He YN, Han C, et al. Current status and prospects of traditional Chinese medicine combined with stem cell therapy for chronic kidney disease[J]. Front Pharmacol, 2025, 15: 1505206. doi:10.3389/fphar.2024.1505206
|
| [15] |
束安梅, 高雨嫣, 朱逸晖, 等. 梓醇抑制AGEs刺激肾内皮细胞介导巨噬细胞活化的作用研究[J]. 中国药理学通报, 2020, 36(11): 1513-9. doi:10.3969/j.issn.1001-1978.2020.11.007
|
| [16] |
张春辉, 吕 静. 基于网络药理学探讨参芪地黄汤治疗慢性肾脏病作用机制[J]. 实用中医内科杂志, 2023, 37(1): 8-12, 后插4-后插8. doi:10.13729/j.issn.1671-7813.Z20220228
|
| [17] |
Liu ZH, Xu QY, Wang Y, et al. Catalpol from Rehmannia glutinosa Targets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis[J]. Am J Chin Med, 2024, 52(5): 1451-85. doi:10.1142/s0192415x24500575
|
| [18] |
许 原, 王 冰, 任 路, 等. 基于网络药理学的熟地黄-山茱萸药治疗阿尔茨海默病的作用机制分析[J]. 实用中医内科杂志, 2021, 35(11): 9-11, 147-8.
|
| [19] |
章新友, 陈晴晴, 唐琍萍. 熟地黄调节AMPK/mTOR信号通路对环磷酰胺诱导早发性卵巢功能不全小鼠的影响[J]. 中药材, 2024, 47(8): 2072-6.
|
| [20] |
何 莹, 唐赛男, 张 敏, 等. 淫羊藿苷通过TNC/Wnt/β-catenin通路延缓慢性肾脏病进程中的保护作用[J]. 时珍国医国药, 2024, 35(7): 1578-81.
|
| [21] |
Liang Y, Qu LY, Liu ZJ, et al. The IRE1/JNK signaling pathway regulates inflammation cytokines and production of glomerular extracellular matrix in the acute kidney injury to chronic kidney disease transition[J]. Mol Biol Rep, 2022, 49(8): 7709-18. doi:10.1007/s11033-022-07588-7
|
| [22] |
Liu YJ, Wang WK, Zhang JT, et al. JAK/STAT signaling in diabetic kidney disease[J]. Front Cell Dev Biol, 2023, 11: 1233259. doi:10.3389/fcell.2023.1233259
|
| [23] |
Yi HA, Jiang YB, Li W, et al. Scutellarin prevents obesity-induced renal fibrosis via reduced activation of AP-1[J]. J Transl Med, 2025, 23(1): 611. doi:10.1186/s12967-025-06616-x
|
| [24] |
Zhang JQ, Li YY, Zhang XY, et al. Cellular senescence of renal tubular epithelial cells in renal fibrosis[J]. Front Endocrinol, 2023, 14: 1085605. doi:10.3389/fendo.2023.1085605
|
| [25] |
Park JY, Yoo KD, Bae E, et al. Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis[J]. Am J Physiol Renal Physiol, 2022, 322(5): F553-72. doi:10.1152/ajprenal.00595.2020
|
| [26] |
Pan J, Shi M, Guo F, et al. Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease[J]. Life Sci, 2021, 285: 119946. doi:10.1016/j.lfs.2021.119946
|
| [27] |
Zhang JH, Peng JQ, Zhang T, et al. Identification of the Main Chemical constituents and mechanism of Renshen Guben oral liquid against Renal Fibrosis[J]. Chin Med, 2023, 18(1): 56. doi:10.1186/s13020-023-00762-4
|
| [28] |
Bhadange R, Dagar N, Gaikwad AB. Levosimendan mitigates renal fibrosis via TGF-β1/Smad axis modulation in UUO rats[J]. Biomed Pharmacother, 2025, 187: 118124. doi:10.1016/j.biopha.2025.118124
|
| [29] |
Jia JH, Chen JF, Wang GL, et al. Progress of research into the pharmacological effect and clinical application of the traditional Chinese medicine Rehmanniae Radix [J]. Biomed Pharmacother, 2023, 168: 115809. doi:10.1016/j.biopha.2023.115809
|
| [30] |
王琳琳, 田 萍, 张 薇, 等. 地黄醇提物通过激活SIRT1/Nrf2/HO-1信号通路改善CUMS大鼠抑郁样行为[J]. 中国药学杂志, 2025, 60(12): 1269-78. doi:10.11669/cpj.2025.12.007
|